ImmunoGen Inc (IMGN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ImmunoGen Inc (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9899
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ImmunoGen Inc (ImmunoGen) is a clinical-stage biotechnology company that focuses on the development of antibody-drug conjugate therapies for the treatment of cancer. The company’s lead product candidate, mirvetuximab soravtansine, a folate receptor alpha (FRa) intended for the treatment of platinum-resistant ovarian cancer and other types of solid tumors, and in Phase 1b/2 testing in combination regimens. Its other pipeline products include IMGN779, a CD33-targeting product candidate for acute myeloid leukemia (AML); and IMGN632 for AML, B-cell acute lymphocytic leukemia, myelodysplastic syndrome and other CD123-positive malignancies. It also carries out early state programs in the areas of solid and liquid tumors. The company has partnership with various pharmaceutical companies to develop and commercialize anticancer compounds. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen Inc (IMGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Licensing Agreements 17
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
Equity Offering 20
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
Debt Offering 27
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Asset Transactions 28
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc – Key Competitors 30
ImmunoGen Inc – Key Employees 31
ImmunoGen Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 02, 2018: ImmunoGen reports recent progress and third quarter 2018 operating results 33
Jul 27, 2018: ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results 35
May 04, 2018: ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results 37
Feb 09, 2018: ImmunoGen Reports Pipeline Progress and 2017 Operating Results 39
Nov 03, 2017: ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results 41
Jul 28, 2017: ImmunoGen Reports Recent Progress and Second Quarter 2017 Operating Results 43
May 05, 2017: ImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results 45
Feb 17, 2017: ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016 47
Corporate Communications 49
Apr 25, 2018: ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer 49
Jan 23, 2017: ImmunoGen Announces Departure of Sandra Poole 50
Product News 51
03/14/2018: ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
ImmunoGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 12
ImmunoGen Enters into Research Agreement with Merck 13
Ventana Medical Systems Enters into Co-Development Agreement with ImmunoGen 14
CytomX Therapeutics Enters Into Co-Development Agreement With ImmunoGen fOR Probody-Drug Conjugates Therapies 15
Takeda Enters into Licensing Agreement with ImmunoGen 17
CytomX Therapeutics Exercises Option for Licensing Agreement with ImmunoGen 18
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 19
ImmunoGen Raises USD150.7 Million in Public Offering of Shares 20
ImmunoGen Raises USD108.4 Million in Public Offering of Shares 22
ImmunoGen Plans to Raise up to USD50 Million in Public Offering 24
ImmunoGen Completes Public Offering Of Common Stock For US$100 Million 25
ImmunoGen Raises USD100 Million in Private Placement of 4.5% Notes Due 2021 27
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 28
TPG Special Situations Partner to Acquire Kadcyla Royalty Rights from ImmunoGen for USD200 Million 29
ImmunoGen Inc, Key Competitors 30
ImmunoGen Inc, Key Employees 31
ImmunoGen Inc, Subsidiaries 32

List of Figures
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ImmunoGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ImmunoGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ImmunoGen Inc (IMGN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EnviroMission Limited (EVM)-エネルギー分野:企業M&A・提携分析
    Summary EnviroMission Limited (Enviro) is a renewable energy company that develops Solar Tower Technology (STT). It owns the license to STT across the world (excluding in China). The STT integrates the use of solar air collector and central updraft tower, to generate solar induced convective flow. I …
  • Dignity Health-製薬・医療分野:企業M&A・提携分析
    Summary Dignity Health is a healthcare service provider that offers patient care services. The center provides health care services that include allergy, behavioral health, anesthesiology, cardiology, chronic care, geriatrics, dermatology, emergency medicine, endocrinology, gastroenterology, immunol …
  • Sports Direct International Plc:企業の戦略・SWOT・財務情報
    Sports Direct International Plc - Strategy, SWOT and Corporate Finance Report Summary Sports Direct International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Novanta Inc (NOVT):医療機器:M&Aディール及び事業提携情報
    Summary Novanta Inc (Novanta), formerly GSI Group Inc is a medical device company that manufactures and markets precision photonics, motion control components and subsystems. The company provides laser products, medical technologies, and precision motion products. It offers laser sources and beam de …
  • Capri Holdings Ltd:企業の戦略・SWOT・財務分析
    Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Arch Capital Group Ltd.:戦略・SWOT・企業財務分析
    Arch Capital Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Arch Capital Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • InterContinental Hotels Group Plc:企業の戦略・SWOT・財務情報
    InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report Summary InterContinental Hotels Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Hospitality Properties Trust:企業のM&A・事業提携・投資動向
    Hospitality Properties Trust - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hospitality Properties Trust Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Vaccibody AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Vaccibody AS (Vaccibody) is a vaccine company that provides discovery and development of novel immunotherapies, prophylactic and therapeutic vaccines. The company develops VB10.16, a DNA based immunotherapy targeting malignancies caused by human papilloma virus. It conducts exploratory safet …
  • Paragon Offshore Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Paragon Offshore Plc (Paragon Offshore) is an oil and gas company that offers offshore drilling rigs. The company provides contract drilling, maintenance and fleet management services. It operates through a fleet of rigs including Jackup rigs, Drillships and semi submersible rigs. Paragon Of …
  • Best Buy Co, Inc.:企業のM&A・事業提携・投資動向
    Best Buy Co, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Best Buy Co, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Antibe Therapeutics Inc (ATE)-医療機器分野:企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • Energy Recovery Inc (ERII):企業の財務・戦略的SWOT分析
    Energy Recovery Inc (ERII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Accuray Inc (ARAY):製品パイプライン分析
    Summary Accuray Inc (Accuray) carries out the development, manufacture and sale of personalized treatment solutions for radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. The company’s major produc …
  • Digital China Holdings Limited:企業の戦略・SWOT・財務分析
    Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Digital China Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • McPherson’s Ltd (MCP):企業の財務・戦略的SWOT分析
    McPherson's Ltd (MCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Maxim Power Corp. (MXG):企業の財務・戦略的SWOT分析
    Maxim Power Corp. (MXG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sri Lanka Telecom PLC (SLTL.N0000):企業の財務・戦略的SWOT分析
    Sri Lanka Telecom PLC (SLTL.N0000) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • BioArctic AB (BIOA B):製薬・医療:M&Aディール及び事業提携情報
    Summary BioArctic AB (BioArctic), formerly BioArctic Neuroscience AB, is a biopharma company that develops new immunotherapeutic treatments for patients with central nervous system disorders. The company develops drugs for neurological disorders such as Parkinson’s disease, Alzheimer’s disease and s …
  • Evergreen Fibreboard Berhad:企業の戦略・SWOT・財務情報
    Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report Summary Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆